These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33363284)

  • 21. COVID-19 convalescent plasma.
    Tobian AAR; Cohn CS; Shaz BH
    Blood; 2022 Jul; 140(3):196-207. PubMed ID: 34695186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
    Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Liu H; Ma ZM; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; Ramiro de Assis R; Yee JL; Nham PB; Ardeshir A; Deere JD; Jain A; Felgner PL; Coffey LL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
    PLoS Pathog; 2022 Apr; 18(4):e1009925. PubMed ID: 35443018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient.
    Mirihagalle N; Parajuli P; Sundareshan V; Saha D; Shah A; Chua F; Waqar S; Prakash V; Tobian AAR; Bloch EM; Katz LM; Goel R
    Transfus Apher Sci; 2021 Oct; 60(5):103180. PubMed ID: 34247970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.
    Fazeli A; Sharifi S; Mohammadi S; Bahraini M; Arabkhazaeli A; Jelveh N; Eshghi P
    Transfus Apher Sci; 2022 Apr; 61(2):103302. PubMed ID: 34774440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
    Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
    Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action.
    Baros-Steyl SS; Al Heialy S; Semreen AH; Semreen MH; Blackburn JM; Soares NC
    Proteomics; 2022 Sep; 22(18):e2200118. PubMed ID: 35809024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
    De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
    Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
    Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
    Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
    Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
    Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns.
    Chen B; Xia R
    Vox Sang; 2020 Aug; 115(6):507-514. PubMed ID: 32516839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.
    Hervig TA; Flesland Ø; Nissen-Meyer LSH
    Transfus Apher Sci; 2022 Aug; 61(4):103487. PubMed ID: 35778352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis.
    Wardhani SO; Fajar JK; Wulandari L; Soegiarto G; Purnamasari Y; Asmiragani A; Maliga HA; Ilmawan M; Seran G; Iskandar DS; Ndapa CE; Hamat V; Wahyuni RA; Cyntia LOS; Maarang FM; Beo YA; Adar OA; Rakhmadhan IM; Shantikaratri ET; Putri ASD; Wahdini R; Broto EP; Suwanto AW; Tamara F; Mahendra AI; Winoto ES; Krisna PA; Harapan H
    F1000Res; 2021; 10():64. PubMed ID: 34136130
    [No Abstract]   [Full Text] [Related]  

  • 36. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
    Al-Tawfiq JA; Arabi Y
    Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
    Bagri A; de Assis RR; Tsai CT; Simmons G; Mei ZW; Von Goetz M; Gatmaitan M; Stone M; Di Germanio C; Martinelli R; Darst O; Rioveros J; Robinson PV; Ward D; Ziman A; Seftel D; Khan S; Busch MP; Felgner PL; Corash LM
    Transfusion; 2022 Mar; 62(3):570-583. PubMed ID: 35128658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
    Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K
    Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.